STAGE III LUNG CANCER AJCC V8

This trial investigates whether adding papaverine—a drug traditionally used as a muscle relaxant—to standard chemoradiation can improve treatment for people with stage II to III non-small cell lung cancer. Papaverine targets the energy factories inside cancer cells (mitochondria)…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This phase 3 trial tests whether adding a precise, high-dose radiation treatment (SBRT) to standard chemoradiation and immunotherapy improves survival for people with locally advanced non-small cell lung cancer that cannot be surgically removed. About 474 participants will be ran…

This study tests a combination of two targeted drugs—sotorasib and trastuzumab deruxtecan—in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the combo works at shrinking tumors. About 37 …

This phase II trial tests whether adding an experimental antibody called GT103 to the immunotherapy drug pembrolizumab can help people with advanced STK11-mutant non-small cell lung cancer. The study enrolls 28 adults whose cancer has worsened despite prior pembrolizumab treatmen…

This study tests whether adding the experimental drug TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can help shrink tumors and extend survival in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, making t…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This study tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) in people with a specific type of advanced lung cancer (LKB1-mutant adenocarcinoma) that has stopped responding to standard treatment. The goal is to see if this t…

This early-phase trial tests a combination of two drugs, carfilzomib and sotorasib, in people with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation. The study aims to find the safest dose and watch for side effects. About 15 participants wh…

This early-phase trial is testing a personalized vaccine made from each patient's unique tumor mutations. The vaccine is given along with an immune booster (poly ICLC) to help the body's T cells attack the cancer. The study includes up to 25 adults with advanced melanoma, breast …

This phase II trial is testing whether giving a combination of two immunotherapy drugs (cemiplimab and fianlimab) before surgery can kill more tumor cells in people with stage IB to IIIB non-small cell lung cancer. About 60 participants will receive the drugs intravenously, then …

This phase II trial tests whether adding local treatments like surgery or radiation to the immunotherapy drug durvalumab can help control stage III non-small cell lung cancer that has progressed after chemoradiation and durvalumab. About 51 participants with 3 or more growing tum…

This phase II trial tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control advanced non-small cell lung cancer when immunotherapy alone starts to show signs of failing. About 20 adults whose cancer has progressed while on standard immunotherapy d…

This study tests whether the drug canakinumab can prevent lung cancer in 50 people who have suspicious lung nodules that haven't gone away. Participants receive the drug and are monitored for nodule shrinkage and cancer development. The goal is to see if this approach can stop lu…

This study tests whether a home-based breathing exercise program can help people who have finished treatment for early-stage lung cancer (stages I-III) breathe easier, feel less tired, and stay more active. About 100 survivors will do breathing exercises at home for several weeks…

This study tests whether a yoga program designed for both patients and their family caregivers can improve physical function, fatigue, sleep, mood, and quality of life. It includes 400 people with lung or esophageal cancer who are getting radiation therapy, plus their caregivers.…

This study from Mayo Clinic is looking at how T cells (a type of immune cell) change during anti-PD-1 immunotherapy in people with advanced melanoma, lung cancer, or other solid tumors. Researchers will collect blood and tissue samples from 500 participants to measure specific ma…

This study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung cancer, or g…

This study looks at how chemoradiation for locally advanced lung cancer affects the heart. Researchers will track 100 patients using heart tests, blood samples, and questionnaires. The goal is to see if tailoring treatment based on individual risk can reduce heart problems.

This study tests a communication tool that helps doctors and patients with non-small cell lung cancer work together on treatment decisions. About 100 patients and their doctors will use the tool during appointments to see if it improves how decisions are made and how satisfied pa…

This trial compares two standard surgical techniques for early-stage lung cancer: tying off the pulmonary vein first versus the pulmonary artery first. Researchers want to see which method better reduces circulating tumor DNA (ctDNA) in the blood after surgery, as lower ctDNA may…